Mometasone and Markers of Airway Inflammation
Information source: Creighton University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Intervention: Placebo (Drug); Mometasone Furoate (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Creighton University Official(s) and/or principal investigator(s): Thomas B Casale, MD, Principal Investigator, Affiliation: Creighton University
Summary
A post-marketing study to look at the effects of Asmanex on markers of airway inflammation.
Clinical Details
Official title: The Effects of Mometasone on Markers of Airway Inflammation
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Primary outcome: Exhaled Nitric Oxide
Secondary outcome: Airway Reactivity
Detailed description:
Patients with asthma and not treated with anti-inflammatory medications were studied. This
was a parallel, randomized, placebo-controlled study to investigate the effects of Asmanex
on markers of airway inflammation including exhaled nitric oxide, airway reactivity, FEV1
and nitrates/nitrites and pH in exhaled breath condensate.
Eligibility
Minimum age: 19 Years.
Maximum age: 50 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Asthma
- non-smoker
- FEV1 of at least 60% predicted
Exclusion Criteria:
- Pregnancy or lactation
- Corticosteroid use in past 30 days
Locations and Contacts
Creighton University Medical Center, Omaha, Nebraska 68131, United States
Additional Information
Starting date: August 2005
Last updated: July 3, 2008
|